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Pharmaceutical assistance is essential in health care and a right of citizens according to
Brazilian law and drug policies. The study purpose was to evaluate aspects of
pharmaceutical assistance in public primary health care.
Methods
A cross-sectional study using WHO drug indicators was carried out in Brasília in
2001. From a random sample of 15 out of 62 centers thirty exiting patients per center
were interviewed.
Results
Only 18.7% of the patients fully understood the prescription, 56.3% could read it,
61.2% of the prescribed drugs were actually dispensed, and mean duration of
pharmaceutical dispensing was 53.2 seconds. Each visit lasted on average 9.4 minutes.
Of prescribed and non-dispensed drugs, 85.3% and 60.6% were on the local essential
drug list (EDL) respectively. On average 83.2% of 40 essential drugs were in stock,
and only two centers had a pharmacist in charge of the pharmacy. The mean number
of drugs per prescription was 2.3, 85.3% of prescribed drugs were on the EDL,
73.2% were prescribed using the generic denomination, 26.4% included antibiotics
and 7.5% were injectables. The most prescribed groups were: cardiovascular drugs
(26.8%), anti-infective drugs (13.1%), analgesics (8.9%), anti-asthmatic drugs (5.8%),
anti-diabetic drugs (5.3%), psychoactive drugs (3.7%), and combination drugs (2.7%).
Conclusions
Essential drugs were only moderately available almost 30 years after the first Brazilian
EDL was formulated. While physician use of essential drugs and generic names was
fairly high, efficiency was impaired by the poor quality of pharmaceutical care, resulting




O acesso a medicamentos e seus serviços é indispensável às ações de saúde e um
direito do cidadão segundo a política de medicamentos e a legislação brasileira. O
objetivo do estudo foi avaliar aspectos da assistência farmacêutica na atenção
primária, em centros de saúde.
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Métodos
Estudo transversal utilizando indicadores da assistência farmacêutica propostos
pela Organização Mundial de Saúde, em amostra aleatória de 15 centros de saúde
dos 62 do Distrito Federal, em 2001. Em cada centro foram entrevistados 30 usuários.
Resultados
Apenas 18,7% dos pacientes compreendiam integralmente a prescrição, sendo que
56,3% conseguiam ler a receita. Foram efetivamente dispensados 61,2% dos
medicamentos prescritos, o tempo médio de dispensação foi de 53,2 segundos e o
de consulta 9,4 minutos. Dos medicamentos prescritos, 85,3% pertenciam à Relação
de Medicamentos Essenciais, bem como 60,6% dos não atendidos. Da lista de 40
medicamentos-chave, 83,2% estavam disponíveis. Apenas duas unidades tinham
farmacêutico responsável pela farmácia. O número médio de medicamentos por
prescrição foi de 2,3. Foram prescritos pelo nome genérico 73,2% dos medicamentos
onde 26,4% eram antibióticos e 7,5% injetáveis. Os grupos farmacológicos mais
prescritos foram: cardiovasculares (26,8%), antimicrobianos (13,1%), analgésicos
(8,9%), antiasmáticos (5,8%), antidiabéticos (5,3%), psicoativos (3,7%) e
associações (2,7%).
Conclusões
Após 30 anos da elaboração da primeira relação de medicamentos essenciais no
Brasil, esses ainda estão apenas parcialmente disponíveis na rede pública, inclusive
os destinados a doenças crônicas. Os prescritores utilizam a relação atualizada e
nomes genéricos, mas a eficiência das ações de assistência farmacêutica está
seriamente comprometida pelos baixos níveis de compreensão dos pacientes e pela
dificuldade de acesso.
INTRODUCTION
Brazil is a middle income country showing sig-
nificant economic growth while it has one of the
most markedly uneven income distributions in the
world. This pattern of economic growth has led to
grossly unequal access to medical and pharmaceu-
tical care.7 A profound health reform, established by
the 1988 review of the Brazilian Constitution, cre-
ated a universal publicly-financed health system.
One of its commitments was, in fact, the provision
of pharmaceutical care to the population. Brazil has
developed programs for the production and distri-
bution of essential drugs since the early 1970s. Nev-
ertheless, surveys have showed that most Brazilians
acquire their drugs through private pharmacies, of-
ten at very high costs for their income, and propor-
tionally higher for the poor. According to the na-
tional household survey on access to and utiliza-
tion of health services family income is strongly
correlated with access to health services, either pub-
lic or private.7 Insufficient access to essential drugs
due to inadequacies in acquisition and distribution
and poor physician prescribing have been described
as factors aggravating the unequal access to good
quality pharmaceutical assistance.4,9
Pharmaceutical price regulation in the Brazilian
market was greatly weakened during the 1990s, re-
sulting in massive increases in drug prices, thus in-
creasing the importance of public distribution to
assure access to essential drugs.
Since the first international Essential Drug List
(EDL) was published in 1977, the World Health Or-
ganization (WHO) has disseminated the concept of
essential drugs as a fundamental steppingstone for
improving access, equity, and quality in health care.11
The WHO encourages countries to elaborate their own
drug lists, adjusted to local needs. Brazil has its own
essential drug list since 1974, and its Federal District,
Brasília, recently updated its list in 2000.
The availability of essential drugs is considered
an important indicator of the effectiveness and eq-
uity of health systems. WHO defines the rational
use of drugs as demanding that “(...) the appropriate
drug be prescribed, that it be available at the right
time, at a price people can afford, that it be dispensed
correctly, and that it be taken in the right dose at the
right intervals and for the right length of time. The
appropriate drug must be effective and of accept-
able quality and safety”.16
A number of organizations have worked with the
WHO in the development of methods and indicators
for evaluating essential drug programs at the primary
care level.10 Such methods have been applied in nu-
merous countries in Africa, Latin America and Asia.
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Use in Health Facilities, which delineated a small set
of practical indicators. This manual describes in de-
tail a set of reliable indicators to measure drug use. In
fact, it defines 12 core indicators that measure key
aspects of drug prescribing, patient care, availability
of drugs and drug information at outpatient facili-
ties. These highly standardized indicators do not re-
quire local adaptation.15
This study aimed at evaluating different aspects
of the pharmaceutical assistance in public primary
health care centers of a major urban region in Brazil
using all 12 core drug indicators proposed by the
WHO, as well as some new indicators.
METHODS
Amongst the various possibilities for evaluating
pharmaceutical assistance, the method delineated
in the manual How to investigate drug use in Health
Facilities15 was chosen as it analyses such aspects in
primary services. Furthermore, this method has a
solid validation, feasibility, and ability to capture
relevant aspects of pharmaceutical assistance.
The study was carried out in the Federal District of
Brazil, Brasília, an area of 5,782 km2 and approximately
two million inhabitants. A cross-sectional study was
conducted aiming at describing selected aspects of
the availability and use of essential drugs in the pub-
lic primary care. Methods suggested by the WHO for
rapid and simple analysis of drugs in primary care serv-
ices were used in addition to few new indicators. A
random sample of 15 out of a total of 62 (24%) public
primary health care centers was selected and 30 exit-
ing patients were interviewed at each center, based on
95% confidence interval and an error of ±4.6%. These
centers are part of the Sistema Único de Saúde - SUS
(Brazilian Unified Heath System), whose legal duties
include provision of medical and pharmaceutical care
to the entire population.
Data was collected between July and September
2001. Consecutive patients leaving the pharmacy
after the researcher’s arrival were invited to partici-
pate up to a total of 30 subjects were obtained. Pa-
tients were included when they had been in a visit,
received a prescription and were over 16 years of
age. The University of Brasília and the Research
Ethics Committee of the Federal District Department
of Health approved the study and all patients signed
an informed consent.
All interviews were performed by the same re-
searcher, and other data collected were by especially
trained pharmacy students. The Essential Drug List
of the Federal District Department of Health was used
and a subset of 40 drugs considered most important
for primary care was selected by researchers after
consultation with local experts and the local Essen-
tial Drug List (Annex).
In addition to the indicators suggested by the
WHO, data concerning demographics of the sam-
pled population, presence of a pharmacist, pharma-
cological groups and most prescribed drugs, identi-
f ication of non-dispensed drugs and prescribed
drugs that are not in the local Essential Drug List
were also collected. The classification of pharma-
cological groups followed that of the National Es-
sential Drug List.
Prescriptions were considered legible through a
generous estimate if the patient was able to read the
name and dosage of at least one of the drugs. Over-
all knowledge was considered positive if a patient
knew the drug name, dose and duration of treat-
ment.10,15 The unit of analysis was the health center.
Instruments were developed and applied after pre-
testing. Statistical analysis was carried out to compare
knowledge of the prescribed drug between different
educational levels using the chi-square (χ2) test and
p<0.05 was considered statistically significant.
RESULTS
Characteristics of Health Centers
The health care centers have relatively similar
physical and human resource infrastructures. All but
one of the centers studied had small scale pharma-
cies with limited space for storage and dispensing.
The drugs were stored on metal or wood shelves.
Pharmacies were generally easily accessible to the
population and patients were served at a small stand
often with a glass window. Stocks were replenished
monthly after presenting maps and standardized re-
quests following a schedule with the option of mak-
ing additional requests. Most drugs were dispensed
without the secondary packages or package inserts.
In all visited units, drugs for special programs, such
as Hansen’s disease, tuberculosis, sexually transmit-
ted diseases or Aids, were stored separately outside
the pharmacy. Local regulation also limited dispen-
sation to a 30-day supply. In all but two centers,
drugs were dispensed by one pharmacy attendant
and lines were frequent.
Characteristics of the patients
A total of 450 patients were interviewed, of which
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72.7% were female. A higher rate of refusal to par-
ticipate was seen among males but it was not quan-
tified. Patients were 38% between 16 and 30 years
of age, 28.9% between 31 and 45, 18.9% between
46 and 60 and 14.4% older than 61 years. Of them,
42 (9.3%) were illiterate, 168 (37.3%) had 1-4 years
of schooling, 130 (28.9%) had 5-8 years, 97 (21.5%)
had initiated or completed high school, and 13
(2.9%) had some higher education.
Indicators of patient care
Of all groups of indicators, those related to infor-
mation and patient care had the poorest results (Ta-
ble 1). Only 61.2% of prescribed drugs were actu-
ally dispensed in the pharmacy. This indicator ranged
from a low 39% in one health center to a maximum
of 73%. Visit times were also short, 9.42 minutes for
medical care and 53.9 seconds for drug dispensing.
Patient’s prescription knowledge was extremely low.
Only 18.7% of all patients fully understood the pre-
scription (Table 2), and even among those at uni-
versity level, knowledge was quite low (38.5%). A
high proportion of prescriptions were illegible; i.e.,
only 56.2% of patients were able to read them.
When viewed sequentially, patients obtained only
61% of their prescribed drugs in the public pharmacy,
and only 18% on average understood their use. Such
findings suggest that a mere 11% of drugs prescribed
through health care centers were both received and
had their proper use understood by the patient.
Indicators of the health services
The essential drug list was available in 60% of
the centers, but even when available it was not of-
ten distributed to prescribers. Of the 40 key drugs
studied (Annex), an average of 83.2% was in stock,
but interruptions in the supply of widely used drugs
such as hypertensive, diabetes mental illness or
asthma drugs were common. Stocks ranged from
67.5% to 90%. Only two out of 15 pharmacies had a
on-site pharmacist though this is legally required.
Prescribing indicators
For 450 patients interviewed, a total of 1,024
drugs were prescribed with a mean of 2.3 drugs per
patient. About one in four prescriptions (26.4%)
included an antibiotic and 7.5% an injectable drug,
most consisting of insulin or penicillin. Antibiot-
ics most prescribed were amoxicillin and sulfam-
ethoxazole-trimethoprim. Prescribers seemed to
have reasonably complied with the essential drug
list: 85.3% drugs prescribed were from the list. Pre-
scribing by generic name is mandatory in the Bra-
zilian public health service and compliance to this
recommendation was also fairly high, 73.2%, or
full compliance.
The study evaluated data not included in the WHO
drug indicator proposal, such as highly prescribed
drugs, drugs on the essential drug list which were not
dispensed, drugs frequently prescribed but were not
included in the essential drug list, and availability of
pharmacist. The most highly prescribed pharmaco-
logical group was cardiovascular drugs (26.8%). The
ACE inhibitors (captopril and enalapril) were the
most prescribed antihypertensive treatments, 25.9%
of all cardiovascular prescriptions, followed by hy-
drochlorothiazide and propranolol, 19.7% and 5.1%
respectively. There were also 28 prescriptions for a
variety of irrational combination drugs, representing
2.7% of drugs prescribed.
The second additional aim was to identify drugs
on the essential drug list which were not dispensed
to identify priorities for supply management. The
leading non-dispensed drugs were paracetamol (42
Table 1 - Indicators of patient care in health centers of Brasília, Brazil, 2001.
Health center Drug dispensed Visit time Dispensing time Prescription legibility Patient knowledge
(%) (minutes) (seconds) (%) (%)
Mean 61.2 9.4 53.9 56.2 18.7
Maximum 73.0 12.6 96 70.0 30.0
Minimum 39.4 6.4 40 40.0 6.7
Table 2 - Education and prescription knowledge, public health centers of Brasília, Brazil, 2001.
Educational level n Prescription knowledge
N (%)
No formal education/ illiterate 42 0 (0)
1-4 years of schooling 168 30 (17.8)
5-8 years of schooling 130 27 (20.8)
Incomplete/complete high school 97 22 (22.7)
Incomplete/complete university 13 5 (38.5)





Pharmaceutical assistance in Brazil
Naves JOS & Silver LD
prescriptions), followed by captopril (36), phenot-
erol drops (11), cephalexin (eight), diclofenac
(eight), and metformin (seven). Another aim was to
identify the most prescribed drugs which were not
included on the essential drug list. The most pre-
scribed drugs in this category were metamizole (19
prescriptions), indapamide (nine) and nystatin vagi-
nal ointment (seven).
DISCUSSION
The study shows both progress and serious defi-
ciencies in assuring access to essential drugs in this
major urban center. Significant progress has clearly
been achieved in assuring a fair drug stock for most
primary care centers, physician’s compliance with
the Essential Drug List, and use of the generic de-
nomination while prescribing. However, there is still
much to be improved. Yet Brasília seems to be ahead
of other countries experiences.3,6,11 In these research-
ers’ experience, when doctors can rely on having
essential drugs in stock in their centers, most will-
ingly prescribe these drugs and use generic names
in order to facilitate patient drug access.11
Nevertheless, this study found that 38.8% prescrip-
tions, of which 60.6% were essential drugs, were
still not filled. Such finding illustrates the need for
improving both financing and managing of the pub-
lic essential drug supply system. The Brazilian uni-
fied health system basic principles of universal ac-
cess, equity and integral care are clearly not yet ful-
filled in this area. Other studies carried out in Brazil
have similarly identified only a partial ability to
dispense prescribed drugs.2,12,13,* It suggests serious
problems in planning and logistics for drug procure-
ment and distribution. These lead to interruptions
in supply, losses, and high expenditures for low-pri-
ority medicines. No pharmacy was found to record
the unmet needs of patients. Implementing a simple
system to record these needs could clearly help to
better supply management.
Hypertension, diabetes, and asthma, major causes
of morbidity and hospitalization, showed an impor-
tant therapeutic drug gap. While the essential drug
list includes asthma inhalers and prednisolone oral
solution, these were not available in all centers. Al-
though captopril, phenoterol, and metformin are es-
sential drug treatments for hypertension, asthma,
and diabetes – three of the most common chronic
diseases – lack of treatment continuity almost cer-
tainly generates significant suffering and costs to
the health care system, usually in the form of pre-
ventable morbidity and hospitalization.8 Similar
results were seen in different regions of Brazil and
other developing countries.1-3,12,13
In the most highly prescribed pharmacological
group of cardiovascular drugs, a deviation from pre-
scribing recommendations was observed. Although
diuretics and beta-blockers are recommended as first
choice treatment for hypertension, ACE inhibitors
were the most prescribed antihypertensive treatment.
The observed proportion of antibiotics (26.4%) and
injectable drugs (7.5%) prescribed may be consid-
ered acceptable according to WHO recommendations
(20-30% and less than 10%, respectively).9,15 Moreo-
ver, most antibiotics and injectable drugs prescribed
were recommended for primary care treatment.
Only three centers studied distributed drugs act-
ing on the central nervous system. This represents a
significant access barrier to patients with mental ill-
ness, including epilepsy and Parkinson’s disease.
Also, it was found that only seven of the 62 health
centers stocked these products. Patients with com-
mon conditions such as schizophrenia, Parkinson’s
disease, depression, and epilepsy are often required
to travel far to obtain their medicines.
Drugs for specific vertical programs such as tu-
berculosis and Hansen’s disease, as well as for con-
traception programs, were regularly supplied to the
centers but they were only available outside the
pharmacies. Local regulation also limits dispensa-
tion to a 30-day supply creating a care barrier for
patients with chronic diseases. This is significantly
aggravated due to the frequent lack of essential drugs.
The most dramatic problems identified were related
to the extremely poor level of patient knowledge and
understanding. Less than one in five patients under-
stood what drug they were to take and how to take it.
Similar results were found in other Brazilian cities such
as Campo Grande, Salvador, Ribeirão Preto, and
Fortaleza.2,12,13,* This low level of information can have
serious consequences regarding the effectiveness and
efficiency of the investment in essential drugs. Silva
et al14 reported that, after outpatient visits in Rio Grande
do Sul, only 34% had good knowledge regarding the
drugs obtained.14 According to Fletcher, the term com-
pliance refers to the degree in which patients follow
the prescribed medical advice. Although initial analy-
sis indicates that noncompliance to prescribed actions
might suggest negligence or unwillingness to submit
to medical advice, in fact many factors may contribute
to that such as inadequate knowledge or prescription
understanding.5 That, in turn, may be related to factors
*Pacheco F,  Aguiar MGG, Queiroa AM. Diagnóstico da assistência farmacêutica no Estado da Bahia. Instituto de Saúde Coletiva, Universidade Federal da Bahia; 1998.
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such as short visit and dispensing times, no pharma-
ceutical care practices in place, no pharmacy-gener-
ated labelling at the time of prescription, high fre-
quency of illegible prescriptions, illiteracy, poorly
trained workers performing the task of drug dispens-
ing and low population schooling.8 In this study,
knowledge was not significant correlated with the level
of education. Although the former was also not sig-
nificantly correlated to other factors, this likelihood
can not be excluded and should be analysed as a
whole. Visit times were short, 9.42 minutes for medi-
cal care and 53.9 seconds for drug dispensing, both
well below the ideal.4
Pharmacies’ physical infrastructure was also found
to be not conducive to activities of patient orienta-
tion and human resources. Drug dispensing was per-
formed on average at the very high rate of 53.2 sec-
onds. In a similar study in Ethiopia, dispensing times
were found to be at 1.9 minutes (±0.6), having a posi-
tive effect on patient satisfaction and knowledge of
drug usage.3
High proportion of illegible prescriptions is another
problem. Only 56.2% of the patients were able to
read the prescription, which is the main or only source
of drug usage information in Brazil. Most products
were dispensed without secondary packaging, prod-
uct inserts, or any pharmacy-generated labels. In Bra-
zil, conversion of the physician’s prescription into
any kind of patient label is not customary in public
or private pharmacies. Pharmacy labelling of dis-
pensed drugs with legible and easily understood iden-
tification and use instructions, accompanied by ver-
bal explanation, may potentially be an important and
low cost intervention for improving rational drug use
in the short- and medium-term.11
An additional factor which may create difficulties
is that while physician prescriptions usually included
generic names, products were often labelled with
brand names. This might change from month to month,
increasing error risks.
The WHO drug indicators were useful for captur-
ing important aspects of pharmaceutical care.16 These
methods can identify the level of supply but do not
provide by themselves the causes of inadequate sup-
ply. The reasons of inadequate supply are important
and need to be identified and corrected in order to
improve access. Evaluating prescribed drugs with
unmet demand and those not listed on the Essential
Drug List, were considered useful for evaluating in-
sufficient supply. The prescription of drugs outside
the list can reflect either poor prescribing habits, lack
of physician compliance or a poorly formulated list
and this analysis helps to identify which is the case.
Other studies in Brazil have found prescribing pre-
dominantly from the EDL, such as in Campo Grande
(92.7%), Salvador (67.6%), Ribeirão Preto (80.0%)
and Fortaleza (70.2%).2,12-14
Availability of a pharmacist is not necessarily
linked to patient outcomes but was a useful indica-
tor given law requirements in Brazil. Furthermore,
drugs acting on the central nervous system, how-
ever necessary, are often not dispensed when there
is no pharmacist available. When available, their
role was limited to supply management and law con-
trols, especially on controlled substances, with a
small participation in promoting rational drug use
or direct patient care. This also needs to be consid-
ered as has been recommended by many for address-
ing the role of pharmacists.17
This is a service-based method, which does not
take into account population access through pri-
vate health services, or even public secondary or
tertiary care facilities. The study conclusions are,
therefore, limited to access to essential drugs via
the public primary care system.
In summary, the study suggests that while an im-
proved drug supply is critically needed, major progress
in the quality of pharmaceutical assistance can also be
achieved by relatively low cost through investments
in improving information to patients and more rational
use.8 Improvement of physical infrastructures, provid-
ing better communication between the dispenser and
patients having difficulties or proper stocking, and
personnel education in rational drug use are also key
steps for improving pharmaceutical service. Inadequate
functioning of the essential drug system forces patients
to resort to the private drug market using their per-
sonal finances to cover far higher cost, or to remain
untreated. The consequences for health and govern-
ment health spending on preventable illnesses are un-
known. However, the reliable distribution of AIDS treat-
ment drugs through the public system in Brazil has
lead to excellent results, significantly reducing AIDS-
related hospitalizations, incidence of opportunistic in-
fections, and mortality.
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1. Acetyl salicylic acid, 100 mg tab.
2. Acetyl salicylic acid, 500 mg tab.
3. Aminophylline, 100 mg tab.
4. Amoxicillin, 500 mg cap.
5. Amoxicillin powder for suspension, 250 mg/ 5 ml oral bottle
6. Benzathine benzylpenicillin powder for suspension, 1,200,000 IU bottle/amp. inj.
7. Procaine benzylpenicillin + Potassium benzylpenicillin suspension for suspension, 300,000 + 100,000 IU
bottle/amp. inj.
8. Captopril, 12.5 mg tab.
9. Captopril, 50 mg tab.
10. Cimetidine, 200 mg tab.
11. Dexamethasone cream, 0.1% tube
12. Dexclorpheniramine, 2 mg tab.
13. Digoxin, 0.25 mg tab.
14. Erythromycin oral suspension, 125 mg/ 5 ml
15. Erythromycin, 500 mg tab./cap.
16. Glibenclamide, 5 mg tab.
17. Gliclazide, 80 mg tab.
18. Hydrochlorothiazide, 50 mg tab.
19. Aluminum hydroxide, 300 mg tabs or suspension 35.6 mg + 37 mg/ml
20. Hyoscine, 10 mg tab.
21. NPH insulin, 100 IU/ml bottle/amp.
22. Regular human insulin, 100 IU/ml bottle/amp.
23. Levonorgestrel + ethynilestradiol 0.03 mg + 0.15 mg tab.
24. Mebendazole, 100 mg tab.
25. Mebendazole, 100 mg/ 5 ml suspension bottle
26. Metformin, 500 mg or 850 mg tab.
27. Methyldopa, 500 mg tab.
28. Metoclopramide, 10 mg tab.
29. Metronidazole, 250 mg tab.
30. Metronidazole, 200 mg/ 5 ml oral suspension bottle
31. Paracetamol, 750 mg tab.
32. Paracetamol, 100 mg/ml drops
33. Propranolol, 40 mg tab.
34. Oral rehydration solution powder for oral solution 1L bag
35. Salbutamol, 2 mg tab.
36. Salbutamol, 2 mg/ 5 ml syrup bottle
37. Sulfamethoxazole + trimethoprim 400 mg + 80 mg tab.
38. Sulfamethoxazole + trimethoprim 200 mg + 40 mg/ 5 ml oral suspension bottle
39. Ferrous sulfate, 40 mg tab.
40. Ferrous sulfate, 25 mg/ml oral solution drops.
